
U.S. Application No. 09/763,535



Attorney Docket No DECLE26.001APC

Page 1

Date: June 29, 2001

JUL 0 2 2001 11

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

June 29, 2001

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 USC 371

International Application No.: PCT/BE99/00112 August 17, 1999 International Filing Date: August 17, 1998

Priority Date Claimed: PHARMACEUTICAL COMPOSITION FOR TREATING OR Title of Invention:

PREVENTING DIABETES OR CANCER, OR THE WAARDENBURG

SYNDROME

Applicant(s) for DO/EO/US: Rousseau, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 (X) U.S.C. 371.
- Copy of Notification of Missing Requirements and Notification to Comply Under 35 U.S.C. 371 In The United States Designated/Elected Office (DO/EO/US) dated March (X) 29, 2001.
- The present application qualifies for small entity status under 37 C.F.R. § 1.27. (X)
- Sequence Submission Statement. (X)
- Sequence Listing in Computer Readable Form. (X)
- Information Disclosure Statement and Form PTO-1449 with seven (7) references. (X)
- Return prepaid postcard. (X)
- Check \$55.00 for one (1) month extention of time. (X)

U.S. Application No. 09/763,535

International Application No. PCT/BE99/00112

Attorney Docket No. **DECLE26.001APC**

Page 2

Date: June 29, 2001

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment, to Account No. 11-1410.

Mark R. Benedict

Registration No. 44,531

Attorney of Record

O:\DOCS\CMS\CMS-1477.DOC:vb 062701